Literature DB >> 21472305

Apoptosis-inducing activity of compounds screened and characterized from cinobufacini by bioassay-guided isolation.

Dong-Liang Wang1, Fang-Hua Qi, Huan-Li Xu, Yoshinori Inagaki, Yutaka Orihara, Kazuhisa Sekimizu, Norihiro Kokudo, Feng-Shan Wang, Wei Tang.   

Abstract

Cinobufacini (huachansu), an aqueous extract from the skin of the toad Bufo bufo gargarizans Cantor, is a traditional Chinese medicinal preparation widely used in clinical cancer therapy in China. Here, we screened and identified active compounds of cinobufacini and investigated their apoptosis-inducing effect on HepG2 cells. Screening was performed using bioassay-guided isolation. The effects of different fractions on the proliferation of HepG2 cells were detected by the MTT assay. The extraction and isolation of active fractions were performed by chloroform extraction, silica column chromatography, preparative thin-layer chromatography and high-performance liquid chromatography. Nuclear magnetic resonance (NMR) imaging and electron ionization-mass spectrometry (EI-MS) were used to identify the structure of the active compounds. The extent of cell apoptosis was detected by Hoechst 33258 staining and flow cytometric analysis. Western blot analysis was used to detect the expression of the apoptosis-related proteins Bax and Bcl-2. Through bioassay-guided isolation, two compounds were isolated from cinobufacini. NMR and EI-MS data revealed these compounds to be resibufogenin and cinobufagin. Cinobufagin was determined to be the more efficient of the two in inhibiting the proliferation of HepG2 cells. Hoechst 33258 staining and flow cytometric analysis indicated that cinobufagin induced marked changes in apoptotic morphology and significantly increased the proportion of apoptotic cells in HepG2 cells. Western blot analysis showed that cinobufagin up-regulated Bax expression and down-regulated Bcl-2 expression. In conclusion, we screened and identified two anti-proliferation compounds of cinibufacini, resibufogenin and cinobufagin. The most effective compound, cinobufagin, inhibited cell proliferation by inducing the apoptosis of HepG2 cells. This was potentially triggered by regulation of the Bax/ Bcl-2 ratio.

Entities:  

Year:  2010        PMID: 21472305     DOI: 10.3892/mmr_00000323

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  10 in total

1.  Resibufogenin suppresses tumor growth and inhibits glycolysis in ovarian cancer by modulating PIM1.

Authors:  Qian Li; Chuanwu Jiang; Yan Wang; Minghua Wei; Huijin Zheng; Yanqi Xu; Xuegang Xu; Fengyu Jia; Kai Liu; Gang Sun; Jianhua Zang; Ping Mo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-10       Impact factor: 3.000

2.  Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis.

Authors:  Lin Ye; Yongning Jia; K E Ji; Andrew J Sanders; Kan Xue; Jiafu Ji; Malcolm D Mason; Wen G Jiang
Journal:  Oncol Lett       Date:  2015-07-06       Impact factor: 2.967

3.  Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3-kinase/protein kinase B/glycogen synthase kinase 3β signaling pathway.

Authors:  Zhen Lu; Aman Xu; Xiao Yuan; Kaiwei Chen; Likun Wang; Tao Guo
Journal:  Oncol Lett       Date:  2018-06-18       Impact factor: 2.967

4.  Resibufogenin Induces G1-Phase Arrest through the Proteasomal Degradation of Cyclin D1 in Human Malignant Tumor Cells.

Authors:  Masami Ichikawa; Yoshihiro Sowa; Yosuke Iizumi; Yuichi Aono; Toshiyuki Sakai
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

5.  Bufadienolides induce p53-mediated apoptosis in esophageal squamous cell carcinoma cells in vitro and in vivo.

Authors:  Shaohuan Lin; Junhong Lv; Panli Peng; Changqing Cai; Jianming Deng; Haihong Deng; Xuejun Li; Xinyue Tang
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

6.  Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice.

Authors:  Xiaohe Li; Zhun Bi; Shuaishuai Liu; Shaoyan Gao; Yunyao Cui; Kai Huang; Mengying Huang; Jiahe Mao; Lixin Li; Jingjing Gao; Tao Sun; Honggang Zhou; Cheng Yang
Journal:  Front Pharmacol       Date:  2019-09-13       Impact factor: 5.810

7.  Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion.

Authors:  Kunyan He; Guang-Xing Wang; Li-Nan Zhao; Xiao-Fang Cui; Xian-Bin Su; Yi Shi; Tian-Pei Xie; Shang-Wei Hou; Ze-Guang Han
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

8.  Immunomodulatory Effects of Cinobufagin on Murine Lymphocytes and Macrophages.

Authors:  Yang Yu; Hui Wang; Xianhua Meng; Lu Hao; Yue Fu; Linlin Fang; Dan Shen; Xiaomeng Yu; Jingshung Li
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-19       Impact factor: 2.629

9.  Cinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells.

Authors:  Guangxin Zhang; Chao Wang; Mei Sun; Jindong Li; Bin Wang; Chengyan Jin; Peiyan Hua; Ge Song; Yifan Zhang; Lisa L H Nguyen; Ranji Cui; Runhua Liu; Lizhong Wang; Xingyi Zhang
Journal:  Oncotarget       Date:  2016-05-17

10.  Resibufogenin suppresses transforming growth factor-β-activated kinase 1-mediated nuclear factor-κB activity through protein kinase C-dependent inhibition of glycogen synthase kinase 3.

Authors:  Lu Liu; Yang Liu; Xiaojia Liu; Na Zhang; Genxiang Mao; Qingxuan Zeng; Mingxiao Yin; Danqing Song; Hongbin Deng
Journal:  Cancer Sci       Date:  2018-09-23       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.